Delivery Order SPE2DR25D3015-SPE2DR26F4FF6
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,329.32 for Somatuline Depot 120 mg/0.5 ml pharmaceutical product on December 1, 2025, with completion expected by December 22, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The delivery order will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a $39,518.60 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Somatuline Depot 120 mg/0.5 ml injectable medication, with a completion date of September 15, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at approximately $25K to AmerisourceBergen Drug Corp for Somatuline Depot 120 mg/0.5 ml pharmaceutical product, with an ultimate completion date of December 24, 2025. This is a firm fixed-price delivery order under a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, leveraging its established role as a critical pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,823.25 on November 24, 2025, for the supply of Somatuline Depot 120 mg/0.5 ml under firm fixed price terms. The contract, which will be completed by December 16, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 through December 2026. This award was competitively awarded with no...
- The Defense Logistics Agency awarded a $39,518.60 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Somatuline Depot 120 mg/0.5 ml pharmaceutical product, with a completion date of September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Somatuline Depot 120 mg/0.5 mL in the amount of $3,951.86, with a completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was awarded through open competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $19,759.30 to AmerisourceBergen Drug Corp for the supply of Somatuline Depot 120 mg/0.5 ml pharmaceutical product. The contract, awarded on October 22, 2025, with an ultimate completion date of November 13, 2025, utilizes firm fixed price pricing under a non-competitive, non-set-aside arrangement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $4,430.84 to AmerisourceBergen Drug Corp for Somatuline Depot 60 mg/0.2 ml pharmaceutical product on November 28, 2025, with completion scheduled for December 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Somatuline Depot 120 mg/0.5 mL pharmaceutical product. This firm fixed-price delivery order, valued at $3,951.86, represents a non-set-aside competitive award with an ultimate completion date of August 28, 2025. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $5,918.93 delivery order to AmerisourceBergen Drug Corp on November 26, 2025, for the supply of Somatuline Depot 90 mg/0.3 ml injections, with an ultimate completion date of December 18, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The contract will be performed at AmerisourceBergen's corporate...
- SPE2DR25D3015Indefinite Delivery Contract
- SPE2DR25D3015-SPE2DR26F4FF6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,164.65 to AmerisourceBergen Drug Corp for Somatuline Depot 120 mg/0.5 mL pharmaceutical product. This is a firm fixed-price delivery order issued on December 8, 2025, with an ultimate completion date of December 30, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp will perform the delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Somatuline Depot is a specialty pharmaceutical used in endocrine and oncology treatment protocols, consistent with AmerisourceBergen's extensive portfolio of brand-name and generic medications supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 12/7/25 |